BioAtla® uses deep expertise in antibody engineering and proprietary technologies to develop a pipeline of novel drugs that address critical unmet needs in cancer therapy.
The culmination of our technological capabilities is our widely applicable platform technology known as Conditionally Active Biologics (CABs). CAB-designed monoclonal antibodies selectively bind their antigen in the context of diseased tissue by exploiting the unique microenvironment of diseased vs normal tissue. This approach enables improved safety and therapeutic index, and allows higher dosing and thus increased potency and sustained treatment. CAB technology also expands the universe of potential targets for oncology and other diseases by conferring greater specificity for diseased tissue.